482 related articles for article (PubMed ID: 32615817)
1. Biologics in the treatment of pustular psoriasis.
Wang WM; Jin HZ
Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
[TBL] [Abstract][Full Text] [Related]
2. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
3. Biologics for Psoriasis.
Wride AM; Chen GF; Spaulding SL; Tkachenko E; Cohen JM
Dermatol Clin; 2024 Jul; 42(3):339-355. PubMed ID: 38796266
[TBL] [Abstract][Full Text] [Related]
4. Risankizumab (Skyrizi) for psoriasis.
Med Lett Drugs Ther; 2019 Jun; 61(1573):81-83. PubMed ID: 31170118
[No Abstract] [Full Text] [Related]
5. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
6. Review of treatments for generalized pustular psoriasis.
Kearns DG; Chat VS; Zang PD; Han G; Wu JJ
J Dermatolog Treat; 2021 Aug; 32(5):492-494. PubMed ID: 31697211
[TBL] [Abstract][Full Text] [Related]
7. Japanese guidance for use of biologics for psoriasis (the 2019 version).
Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
[TBL] [Abstract][Full Text] [Related]
8. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
9. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.
Hu Y; Chen Z; Gong Y; Shi Y
Clin Drug Investig; 2018 Mar; 38(3):191-199. PubMed ID: 29249053
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
[TBL] [Abstract][Full Text] [Related]
11. Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review.
Rosi E; Fastame MT; Di Cesare A; Prignano F
Expert Opin Biol Ther; 2022 Dec; 22(12):1475-1487. PubMed ID: 35997143
[TBL] [Abstract][Full Text] [Related]
12. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Menter A; Van Voorhees AS; Hsu S
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
14. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.
Maliyar K; Crowley EL; Rodriguez-Bolanos F; O'Toole A; Gooderham MJ
J Cutan Med Surg; 2019; 23(4):428-435. PubMed ID: 30938189
[TBL] [Abstract][Full Text] [Related]
15. Acrodermatitis continua of Hallopeau successfully treated with secukinumab.
Balestri R; Rech G; Tasin L; Rizzoli L; Girardelli CR
J Dermatolog Treat; 2018; 29(sup1):3-5. PubMed ID: 30246571
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report.
Wen P; Liu C; Wang T; Jiang X; Wang P; Wang S
Front Immunol; 2024; 15():1338285. PubMed ID: 38464535
[TBL] [Abstract][Full Text] [Related]
17. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
18. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
19. Biologics in pediatric psoriasis - efficacy and safety.
Dogra S; Mahajan R
Expert Opin Drug Saf; 2018 Jan; 17(1):9-16. PubMed ID: 29022425
[TBL] [Abstract][Full Text] [Related]
20. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.
Sun X; Cui Z; Wang Q; Liu L; Ding X; Wang J; Cai X; Li B; Li X
Autoimmun Rev; 2024 Apr; 23(4):103530. PubMed ID: 38499168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
